세계의 벤다무스틴 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

The global market for Bendamustine was estimated to be worth US$ 416 million in 2024 and is forecast to a readjusted size of US$ 290 million by 2031 with a CAGR of -4.9% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Bendamustine cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Bendamustine is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein.In 2024, global Bendamustine production reached approximately 1.45 m units, with an average global market price of around US$ 287 perunit.

In the face of a rising global burden of hematologic malignancies and the aging population, the opportunity for bendamustine is highly compelling. Incidence increases in chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and other blood cancers create rising demand for chemotherapy agents that combine efficacy with tolerability-exactly where bendamustine shines. Public health bodies and governmental agencies in many countries have updated or expanded treatment guidelines for lymphomas and leukemia, which boosts adoption and standardization of treatments incorporating bendamustine. In parallel, the movement toward combination regimens (chemotherapy plus targeted or immunotherapy) is accelerating; bendamustine's mechanism allows it to pair with these newer modalities, opening up new indication and regimen expansion. Further, the arrival of generics and lifecycle management strategies reduces cost and increases access, especially in emerging markets (Asia-Pacific, Latin America, Southeast Asia) with improving healthcare infrastructure.

Despite strong tailwinds, bendamustine faces significant challenges. First, novel targeted therapies and immunotherapies-such as CAR-T cell therapy, monoclonal antibodies, and small molecule inhibitors-are increasingly taking center stage in treatment guidelines and clinical practice, which can erode bendamustine's share in some indications. Second, adverse effect profiles-bone-marrow suppression, infection risk, etc.-limit its use in frail patients or those with comorbidities. Third, reimbursement, pricing policies and regulatory environments vary widely; in markets with strict price regulation or limited insurance coverage, uptake and profitability are constrained. Fourth, competition from generics post-patent expiry can drive down margins. Finally, maintaining consistent quality, purity and regulatory compliance across manufacturing and supply chain presents both cost and operational risks.

On the downstream side, clinical demand is shifting toward more precise, combination, and convenience-oriented treatment paradigms. Advances in diagnostic technologies-molecular biomarkers, gene sequencing, minimal residual disease (MRD) monitoring-enable earlier intervention and more tailored therapy; bendamustine, when combined with immunotherapy or targeted agents, is increasingly considered in such regimens. Patients and health systems are placing growing importance on the balance between efficacy and toxicity, quality of life, administration convenience, treatment schedule improvements, and the cost of managing side effects. Markets in emerging economies display strong demand for cost-effective, generic or biosimilar versions; in developed markets, newer combinations or recommended regimens (per guidelines) lead the adoption. Outpatient, clinic-based, or home care settings are also increasingly relevant, imposing higher demands on formulation, delivery, and support of bendamustine products.

Bendamustine, as a synthetic small molecule drug, depends upstream on raw materials including alkylating-agent intermediates, purine analog intermediate building blocks, organic chemical reagents, high-purity solvents, and intermediates used in purification and crystallization steps. The alkylating portion may derive from chloro-organic compounds, cyclic alkyl or aziridine / cyclic moiety precursors; the purine analog side requires nucleoside or nucleobase precursors, catalysts, stereo-chemistry control, and minimal impurities. High-purity solvents, metal catalysts or reducing/oxidizing agents are essential, with tight control over residual metals and by-products. Supply stability is influenced by capacity at chemical intermediates or fine chemicals manufacturers, environmental regulation (especially around organic solvent emissions and waste handling), trade and import/export policies, and patent protections or exclusivity in certain synthetic routes. Quality control in the synthesis, purification, crystallization, and intermediate handling steps is critical for final drug stability, safety, and regulatory approval.The gross profit margin of this product is around 80%.

This report aims to provide a comprehensive presentation of the global market for Bendamustine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Bendamustine by region & country, by Type, and by Application.

The Bendamustine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bendamustine.

Market Segmentation

By Company

• Teva
• Eisai
• Eagle Pharmaceuticals
• MundiPharma
• Viatris
• Apotex
• Emcure
• Miracalus Pharma
• Fresenius
• Zhengda Tianqing
• Slayback Pharma
• SYMBIO SEIYAKU
• Hikma Pharmaceuticals
• Natco Pharma
• Medac GmbH

Segment by Type

• 25mg Injection
• 100mg Injection
• Others

Segment by Application

• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Non-Hodgkin's Lymphoma

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Bendamustine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Bendamustine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Bendamustine in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Bendamustine Product Introduction
• 1.2 Global Bendamustine Market Size Forecast
  • 1.2.1 Global Bendamustine Sales Value (2020-2031)
  • 1.2.2 Global Bendamustine Sales Volume (2020-2031)
  • 1.2.3 Global Bendamustine Sales Price (2020-2031)
• 1.3 Bendamustine Market Trends & Drivers
  • 1.3.1 Bendamustine Industry Trends
  • 1.3.2 Bendamustine Market Drivers & Opportunity
  • 1.3.3 Bendamustine Market Challenges
  • 1.3.4 Bendamustine Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Bendamustine Players Revenue Ranking (2024)
• 2.2 Global Bendamustine Revenue by Company (2020-2025)
• 2.3 Global Bendamustine Players Sales Volume Ranking (2024)
• 2.4 Global Bendamustine Sales Volume by Company Players (2020-2025)
• 2.5 Global Bendamustine Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Bendamustine Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Bendamustine Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Bendamustine
• 2.9 Bendamustine Market Competitive Analysis
  • 2.9.1 Bendamustine Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Bendamustine Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bendamustine as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 25mg Injection
  • 3.1.2 100mg Injection
  • 3.1.3 Others
• 3.2 Global Bendamustine Sales Value by Type
  • 3.2.1 Global Bendamustine Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Bendamustine Sales Value, by Type (2020-2031)
  • 3.2.3 Global Bendamustine Sales Value, by Type (%) (2020-2031)
• 3.3 Global Bendamustine Sales Volume by Type
  • 3.3.1 Global Bendamustine Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Bendamustine Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Bendamustine Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Bendamustine Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Chronic Lymphocytic Leukemia
  • 4.1.2 Multiple Myeloma
  • 4.1.3 Non-Hodgkin's Lymphoma
• 4.2 Global Bendamustine Sales Value by Application
  • 4.2.1 Global Bendamustine Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Bendamustine Sales Value, by Application (2020-2031)
  • 4.2.3 Global Bendamustine Sales Value, by Application (%) (2020-2031)
• 4.3 Global Bendamustine Sales Volume by Application
  • 4.3.1 Global Bendamustine Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Bendamustine Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Bendamustine Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Bendamustine Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Bendamustine Sales Value by Region
  • 5.1.1 Global Bendamustine Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Bendamustine Sales Value by Region (2020-2025)
  • 5.1.3 Global Bendamustine Sales Value by Region (2026-2031)
  • 5.1.4 Global Bendamustine Sales Value by Region (%), (2020-2031)
• 5.2 Global Bendamustine Sales Volume by Region
  • 5.2.1 Global Bendamustine Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Bendamustine Sales Volume by Region (2020-2025)
  • 5.2.3 Global Bendamustine Sales Volume by Region (2026-2031)
  • 5.2.4 Global Bendamustine Sales Volume by Region (%), (2020-2031)
• 5.3 Global Bendamustine Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Bendamustine Sales Value, 2020-2031
  • 5.4.2 North America Bendamustine Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Bendamustine Sales Value, 2020-2031
  • 5.5.2 Europe Bendamustine Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Bendamustine Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Bendamustine Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Bendamustine Sales Value, 2020-2031
  • 5.7.2 South America Bendamustine Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Bendamustine Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Bendamustine Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Bendamustine Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Bendamustine Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Bendamustine Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Bendamustine Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Bendamustine Sales Value, 2020-2031
  • 6.3.2 United States Bendamustine Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Bendamustine Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Bendamustine Sales Value, 2020-2031
  • 6.4.2 Europe Bendamustine Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Bendamustine Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Bendamustine Sales Value, 2020-2031
  • 6.5.2 China Bendamustine Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Bendamustine Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Bendamustine Sales Value, 2020-2031
  • 6.6.2 Japan Bendamustine Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Bendamustine Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Bendamustine Sales Value, 2020-2031
  • 6.7.2 South Korea Bendamustine Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Bendamustine Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Bendamustine Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Bendamustine Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Bendamustine Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Bendamustine Sales Value, 2020-2031
  • 6.9.2 India Bendamustine Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Bendamustine Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Teva
  • 7.1.1 Teva Company Information
  • 7.1.2 Teva Introduction and Business Overview
  • 7.1.3 Teva Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Teva Bendamustine Product Offerings
  • 7.1.5 Teva Recent Development
• 7.2 Eisai
  • 7.2.1 Eisai Company Information
  • 7.2.2 Eisai Introduction and Business Overview
  • 7.2.3 Eisai Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Eisai Bendamustine Product Offerings
  • 7.2.5 Eisai Recent Development
• 7.3 Eagle Pharmaceuticals
  • 7.3.1 Eagle Pharmaceuticals Company Information
  • 7.3.2 Eagle Pharmaceuticals Introduction and Business Overview
  • 7.3.3 Eagle Pharmaceuticals Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Eagle Pharmaceuticals Bendamustine Product Offerings
  • 7.3.5 Eagle Pharmaceuticals Recent Development
• 7.4 MundiPharma
  • 7.4.1 MundiPharma Company Information
  • 7.4.2 MundiPharma Introduction and Business Overview
  • 7.4.3 MundiPharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 MundiPharma Bendamustine Product Offerings
  • 7.4.5 MundiPharma Recent Development
• 7.5 Viatris
  • 7.5.1 Viatris Company Information
  • 7.5.2 Viatris Introduction and Business Overview
  • 7.5.3 Viatris Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Viatris Bendamustine Product Offerings
  • 7.5.5 Viatris Recent Development
• 7.6 Apotex
  • 7.6.1 Apotex Company Information
  • 7.6.2 Apotex Introduction and Business Overview
  • 7.6.3 Apotex Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Apotex Bendamustine Product Offerings
  • 7.6.5 Apotex Recent Development
• 7.7 Emcure
  • 7.7.1 Emcure Company Information
  • 7.7.2 Emcure Introduction and Business Overview
  • 7.7.3 Emcure Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Emcure Bendamustine Product Offerings
  • 7.7.5 Emcure Recent Development
• 7.8 Miracalus Pharma
  • 7.8.1 Miracalus Pharma Company Information
  • 7.8.2 Miracalus Pharma Introduction and Business Overview
  • 7.8.3 Miracalus Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Miracalus Pharma Bendamustine Product Offerings
  • 7.8.5 Miracalus Pharma Recent Development
• 7.9 Fresenius
  • 7.9.1 Fresenius Company Information
  • 7.9.2 Fresenius Introduction and Business Overview
  • 7.9.3 Fresenius Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Fresenius Bendamustine Product Offerings
  • 7.9.5 Fresenius Recent Development
• 7.10 Zhengda Tianqing
  • 7.10.1 Zhengda Tianqing Company Information
  • 7.10.2 Zhengda Tianqing Introduction and Business Overview
  • 7.10.3 Zhengda Tianqing Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Zhengda Tianqing Bendamustine Product Offerings
  • 7.10.5 Zhengda Tianqing Recent Development
• 7.11 Slayback Pharma
  • 7.11.1 Slayback Pharma Company Information
  • 7.11.2 Slayback Pharma Introduction and Business Overview
  • 7.11.3 Slayback Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Slayback Pharma Bendamustine Product Offerings
  • 7.11.5 Slayback Pharma Recent Development
• 7.12 SYMBIO SEIYAKU
  • 7.12.1 SYMBIO SEIYAKU Company Information
  • 7.12.2 SYMBIO SEIYAKU Introduction and Business Overview
  • 7.12.3 SYMBIO SEIYAKU Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 SYMBIO SEIYAKU Bendamustine Product Offerings
  • 7.12.5 SYMBIO SEIYAKU Recent Development
• 7.13 Hikma Pharmaceuticals
  • 7.13.1 Hikma Pharmaceuticals Company Information
  • 7.13.2 Hikma Pharmaceuticals Introduction and Business Overview
  • 7.13.3 Hikma Pharmaceuticals Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 Hikma Pharmaceuticals Bendamustine Product Offerings
  • 7.13.5 Hikma Pharmaceuticals Recent Development
• 7.14 Natco Pharma
  • 7.14.1 Natco Pharma Company Information
  • 7.14.2 Natco Pharma Introduction and Business Overview
  • 7.14.3 Natco Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.14.4 Natco Pharma Bendamustine Product Offerings
  • 7.14.5 Natco Pharma Recent Development
• 7.15 Medac GmbH
  • 7.15.1 Medac GmbH Company Information
  • 7.15.2 Medac GmbH Introduction and Business Overview
  • 7.15.3 Medac GmbH Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.15.4 Medac GmbH Bendamustine Product Offerings
  • 7.15.5 Medac GmbH Recent Development

8 Industry Chain Analysis

• 8.1 Bendamustine Industrial Chain
• 8.2 Bendamustine Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Bendamustine Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Bendamustine Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer